Literature DB >> 16631632

Rapid ventricular pacing to lower blood pressure during endograft deployment in the thoracic aorta.

Suwatchai Pornratanarangsi1, Mark W I Webster, Peter Alison, Parma Nand.   

Abstract

Controlled hypotension is critical to the accurate deployment of aortic endografts and safe balloon post-dilation. We describe the use of rapid ventricular pacing during 15 aortic stenting procedures. An immediate and sustained reduction in both phasic and mean blood pressure was achieved in all patients. This procedure has advantages over pharmacologic or other methods of blood pressure reduction.

Entities:  

Mesh:

Year:  2006        PMID: 16631632     DOI: 10.1016/j.athoracsur.2006.01.081

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Think differently: trans-apical platform for TEVAR.

Authors:  Fabio Ramponi; Michael S Stephen; Michael K Wilson; Michael P Vallely
Journal:  Ann Cardiothorac Surg       Date:  2012-09

2.  Impact of rapid ventricular pacing during TAVI on microvascular tissue perfusion.

Authors:  Anna Selle; Hans R Figulla; Markus Ferrari; Wilma Rademacher; Bjoern Goebel; Ali Hamadanchi; Marcus Franz; Andrea Schlueter; Thomas Lehmann; Alexander Lauten
Journal:  Clin Res Cardiol       Date:  2014-06-05       Impact factor: 5.460

3.  Endovascular repair of thoracic aortic injury: current thoughts and technical considerations.

Authors:  W Darrin Clouse
Journal:  Semin Intervent Radiol       Date:  2010-03       Impact factor: 1.513

4.  [Traumatic thoracic aorta rupture: preclinical assessment, diagnosis and treatment options].

Authors:  R Kopp; J Andrassy; S Czerner; A Weidenhagen; R Weidenhagen; G Meimarakis; M Reiser; K W Jauch
Journal:  Anaesthesist       Date:  2008-08       Impact factor: 1.041

5.  Application of rapid artificial cardiac pacing in thoracic endovascular aortic repair in aged patients.

Authors:  Jun Chen; Wenhui Huang; Songyuan Luo; Dahao Yang; Zhengrong Xu; Jianfang Luo
Journal:  Clin Interv Aging       Date:  2013-12-27       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.